References
- Canadian Psychiatric Association. Clinical practice guidelines. Treatment of schizophrenia. Can J Psychiatry 2005;50(13 Suppl. 1):7S-57S
- Dossenbach M, Arango-Dávila C, Silva Ibarra H, et al. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J Clin Psychiatry 2005;66:1021-30
- Cook PE, Goldberg JO, Van Lieshout RJ. Benefits of switching from typical to atypical antipsychotic medications: a longitudinal study in a community-based setting. Can J Psychiatry 2002;47:870-4
- Voruganti L, Cortese L, Owyeumi L, et al. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res 2002;57:201-8
- Williams R, Kopala L, Malla A, et al. Medication decisions and clinical outcomes in the Canadian National Outcomes Measurement Study in Schizophrenia. Acta Psychiatr Scand 2006;113(Suppl. 430):12-21
- American Psychiatric Association. DSM-IV. Diagnostic and Statistical Manual of Mental Disorders, 4th Edn. Washington: American Psychiatric Association, 1994
- Rhoades HM, Overall JE. The semistructured BPRS interview and rating guide. Psychopharmacol Bull 1988;24:101-4
- Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health, 1976: pp. 218–22
- Cooper D, Moisan J, Gaudet M, et al. Ambulatory use of olanzapine and risperidone: a population-based study on persistence and the use of concomitant therapy in treatment of schizophrenia. Can J Psychiatry 2005;50:901-8
- Procyshyn RM, Thompson B. Patterns of antipsychotic utilization in a tertiary care psychiatric institution. Pharmacopsychiatry 2004;37:12-17
- Ganguly R, Kotzan JA, Miller LS, et al. Prevalence, trends and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998–2000. J Clin Psychiatry 2004;65:1377-88
- Haro JM, Edgell ET, Novick D, et al. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr Scand 2005;111:220-31
- Burns T, Christova L, Cooper S, et al. Maintenance antipsychotic medication patterns in outpatient schizophrenia patients: a naturalistic cohort study. Acta Psychiatr Scand 2006;113:126-34
- Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
- Faries D, Ascher-Svanum H, Zhu B, et al. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 2005;5:26
- Usall J, Ochoa S, Araya S, et al. Gender differences and outcome in schizophrenia: a 2-year follow-up study in a large community sample. Eur Psychiatry 2003;18:282-4
- Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med 2005;3:21-31
- Ascher-Svanum H, Zhu B, Faries DE, et al. Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia. BMC Res Notes 2009;2:6
- Novick D, Haro JM, Suarez D et al. Predictors and consequences of adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Research 2009 In Press
- McIntyre RS, Trakas K, Lin D, et al. Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia. Can J Psychiatry 2003;48:689-96